FDA proposes one licence for many versions of a personalised gene-editing therapy

The FDA has published draft guidance that would let a developer license one gene-editing product and later add versions for other patients' mutations on laboratory data, without a new clinical trial. It is aimed at diseases where each mutation is too rare to study on its own.

What has the FDA proposed?

On 27 October the FDA's biologics centre, CBER, issued draft guidance on individualised human genome editing products [1][2]. It covers products for a monogenic disease caused by known pathogenic variants, where the editing components are tailored to each patient's variant but every version aims at the same editing outcome [1]. Such a product can be submitted in one biologics licence application (BLA) that covers several "product variants" [1].

The core idea is an "individualized feature space": the limits within which the variable parts, such as the guide RNA, may change. It is set out in the application, supported by clinical data and tied to pre-defined laboratory criteria for activity and safety [1]. After approval, a new variant inside those limits is treated as a manufacturing change and filed as a supplement with laboratory data. Clinical data are generally not expected when the link between laboratory results and clinical effect is well understood and predictable [1].

Why is the FDA doing this?

In many monogenic diseases, patients carry different mutations in the same gene, and each mutation may be too rare for a conventional trial [1][3]. Treating every tailored version as a separate product was "infeasible" and not necessary, according to Andrew Byrnes, who directs CBER's Division of Gene Therapy 1 [2].

The draft builds on the FDA's 2024 draft guidance on genome-editing products and on three 2026 drafts: a plausible-mechanism framework for individualised therapies, the use of prior knowledge across editing programmes, and sequencing-based safety testing [1][2]. BioPharma Dive links it to the FDA's Rare Disease Framework Initiative and to the personalised CRISPR treatment developed in 2025 for an infant, KJ Muldoon [3].

What does it mean for developers?

1. Design the feature space before the pivotal study. The FDA encourages developers to define it prospectively and discuss it with the agency before pivotal studies [1]. The first trial then has to support the whole space, not one product.

2. Manufacturing and testing carry more weight. The process should make current and future variants without revalidation. Identity tests should confirm the variable parts, lot release needs at least one potency assay, and off-target editing should be assessed for each guide and editor combination with a pre-specified sequencing protocol submitted in the BLA [1].

3. The limits are firm. One mechanism per BLA: a base editor and a reverse transcriptase-based editor cannot share one. Widening the feature space needs a prior approval supplement and possibly clinical data, variants for a different disease need clinical evidence, and the label names the gene variants shown safe and effective in studies [1].

4. Trial design is not covered yet. The FDA says it intends to issue separate guidance on clinical studies [1].

Systemix view: one licence, many patients, many payers

The real opportunity in the FDA draft is what happens after the first approval. Rather than starting from scratch for every new mutation, developers could potentially expand an existing approval using laboratory, analytical and manufacturing evidence. That would be a significant change for rare disease development.

For companies looking at Europe, however, the picture is less straightforward. There is no guarantee that the EMA will follow the FDA's approach or accept the same evidence for additional variants. And even if regulators agree, reimbursement presents another challenge. How will HTA bodies and payers assess a one-time treatment when the number of eligible patients can grow with each newly supported variant?

This is why European market access should be part of the discussion well before pivotal studies begin. Getting regulatory approval is one thing. Building evidence that also convinces payers is another. Developers that consider both from the start will be in a much stronger position.

The FDA is accepting comments on this draft until about 27 November 2026, docket FDA-2026-D-11783 [4].

Related reading

FDA's new rare disease framework: what it means for drug developers

Rare disease drug development is evolving. What does this mean for evidence strategies?

The Joint Clinical Assessment and rare disease

Sources

1. FDA, CBER. Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management. Draft guidance for industry, October 2026.

2. Regulatory Focus (RAPS). FDA issues draft guidance on individualized gene editing products to fill critical gap, 27 October 2026.

3. BioPharma Dive (K. Jensen). FDA unveils guidance for 'plug and play' gene therapies, 28 October 2026.

4. Federal Register. Notice of availability, docket FDA-2026-D-11783, publication date 28 October 2026 (public inspection copy).